We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Becton (BDX) with FlowJo to Provide Cloud Platform Services
Read MoreHide Full Article
Leading global medical technology company, Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced that it has entered into an agreement with FlowJo, LLC, a life science informatics and data analysis company. Per the agreement, the companies would offer the cloud-based platform, FlowJo Envoy alongwith BD FACSymphony, a cell analyzer for their customers.
Stock Performance
Becton has had an impressive run on the bourse over the past one month. The company gained roughly 3.91%, which is higher than the Zacks categorized Medical/Dental-Supplies sub industry’s addition of almost 3.41%. The current level compares favorably with the S&P 500’s return of 1.26% over the same time frame. This, together with a long-term expected earnings growth rate of 11.29%, instills confidence in investors.
The estimate revision trend seems favorable for the stock at this moment, with one estimate moving up in the last 60 days and no downward movement. The above factor indicates chances of a recovery. The current year estimate for the stock stands at 53 cents per share.
Coming back to the news, the collaboration is a sound move from the two companies. The announcement was made at the 32nd Congress of the International Society for Advancement of Cytometry at the Hynes Convention Center in Boston.
The collaboration would bring together Becton’s proprietary FACSymphony cell analyzer and FlowJo Envoy to enable scientists to collaborate, coordinate and execute high-parameter single-cell experiments seamlessly in real-time. This would enable the users to achieve a measurement of up to 50 different characteristics of a single cell. The combination will also enable researchers to improve their workflow, collaborations and store their data in the cloud and share single-cell analysis information in real-time.
Based in Franklin Lakes, NJ, Becton, Dickinson is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. Going forward, BD’s focus on product launches is a significant catalyst in our view. Additionally, its expansion plans, especially in the emerging overseas markets and the acquisition-driven strategy hold considerable promise. On the flipside, lower demand for healthcare products, intensifying competition, significant exposure to foreign exchange volatility and higher debt levels pose major headwinds.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock added roughly 32.8% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 80%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock added roughly 12% over the last three months.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
Image: Bigstock
Becton (BDX) with FlowJo to Provide Cloud Platform Services
Leading global medical technology company, Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced that it has entered into an agreement with FlowJo, LLC, a life science informatics and data analysis company. Per the agreement, the companies would offer the cloud-based platform, FlowJo Envoy alongwith BD FACSymphony, a cell analyzer for their customers.
Stock Performance
Becton has had an impressive run on the bourse over the past one month. The company gained roughly 3.91%, which is higher than the Zacks categorized Medical/Dental-Supplies sub industry’s addition of almost 3.41%. The current level compares favorably with the S&P 500’s return of 1.26% over the same time frame. This, together with a long-term expected earnings growth rate of 11.29%, instills confidence in investors.
The estimate revision trend seems favorable for the stock at this moment, with one estimate moving up in the last 60 days and no downward movement. The above factor indicates chances of a recovery. The current year estimate for the stock stands at 53 cents per share.
Coming back to the news, the collaboration is a sound move from the two companies. The announcement was made at the 32nd Congress of the International Society for Advancement of Cytometry at the Hynes Convention Center in Boston.
The collaboration would bring together Becton’s proprietary FACSymphony cell analyzer and FlowJo Envoy to enable scientists to collaborate, coordinate and execute high-parameter single-cell experiments seamlessly in real-time. This would enable the users to achieve a measurement of up to 50 different characteristics of a single cell. The combination will also enable researchers to improve their workflow, collaborations and store their data in the cloud and share single-cell analysis information in real-time.
Based in Franklin Lakes, NJ, Becton, Dickinson is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. Going forward, BD’s focus on product launches is a significant catalyst in our view. Additionally, its expansion plans, especially in the emerging overseas markets and the acquisition-driven strategy hold considerable promise.
On the flipside, lower demand for healthcare products, intensifying competition, significant exposure to foreign exchange volatility and higher debt levels pose major headwinds.
Zacks Rank & Stocks to Consider
Becton carries a Zacks Rank #3 (Hold).
Better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Align Technology and Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock added roughly 32.8% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 80%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock added roughly 12% over the last three months.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>